Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data

Evo Alemao, Seongjung Joo, Hugh Kawabata, Maiwenn J Al, Paul D Allison, Maureen P M H Rutten-van Mölken, Michelle L Frits, Christine K Iannaccone, Nancy A Shadick, Michael E Weinblatt, Evo Alemao, Seongjung Joo, Hugh Kawabata, Maiwenn J Al, Paul D Allison, Maureen P M H Rutten-van Mölken, Michelle L Frits, Christine K Iannaccone, Nancy A Shadick, Michael E Weinblatt

Abstract

Objective: To evaluate associations between achieving guideline-recommended targets of disease activity, defined by the Disease Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) <2.6, the Simplified Disease Activity Index (SDAI) ≤3.3, or the Clinical Disease Activity Index (CDAI) ≤2.8, and other health outcomes in a longitudinal observational study.

Methods: Other defined thresholds included low disease activity (LDA), moderate (MDA), or severe disease activity (SDA). To control for intraclass correlation and estimate effects of independent variables on outcomes of the modified Health Assessment Questionnaire (M-HAQ), the EuroQol 5-domain (EQ-5D; a quality-of-life measure), hospitalization, and durable medical equipment (DME) use, we employed mixed models for continuous outcomes and generalized estimating equations for binary outcomes.

Results: Among 1,297 subjects, achievement (versus nonachievement) of recommended disease targets was associated with enhanced physical functioning and lower health resource utilization. After controlling for baseline covariates, achievement of disease targets (versus LDA) was associated with significantly enhanced physical functioning based on SDAI ≤3.3 (ΔM-HAQ -0.047; P = 0.0100) and CDAI ≤2.8 (-0.073; P = 0.0003) but not DAS28-CRP <2.6 (-0.022; P = 0.1735). Target attainment was associated with significantly improved EQ-5D (0.022-0.096; P < 0.0030 versus LDA, MDA, or SDA). Patients achieving guideline-recommended disease targets were 36-45% less likely to be hospitalized (P < 0.0500) and 23-45% less likely to utilize DME (P < 0.0100).

Conclusion: Attaining recommended target disease-activity measures was associated with enhanced physical functioning and health-related quality of life. Some health outcomes were similar in subjects attaining guideline targets versus LDA. Achieving LDA is a worthy clinical objective in some patients.

Trial registration: ClinicalTrials.gov NCT01793103.

© 2016 The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.

Figures

Figure 1
Figure 1
Mean modified Health Assessment Questionnaire (MHAQ) disability scores, EuroQol 5‐domain (EQ‐5D) health‐related quality of life scores, and durable medical equipment (DME) use among patients achieving targets (light bars) compared to those not achieving target measures (dark bars). Disease targets were Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP) Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22678/abstract.
Figure 2
Figure 2
Mean modified Health Assessment Questionnaire (MHAQ) disability scores, EuroQol 5‐domain (EQ‐5D) health‐related quality of life scores, and durable medical equipment (DME) use among patients with Disease Activity Score in 28 joints using the C‐reactive protein level (DAS28‐CRP) 5.1; SDAI >26.0; CDAI >22.0.

References

    1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–108.
    1. Eriksson JK, Johansson K, Askling J, Neovius M. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? Ann Rheum Dis 2015;74:648–54.
    1. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77–90.
    1. Centers for Disease Control and Prevention. Arthritis-related statistics. 2016. URL: .
    1. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
    1. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient‐reported outcomes and costs. Arthritis Res Ther 2014;16:R56.
    1. Vermeer M, Kievit W, Kuper HH, Braakman‐Jansen LM, Bernelot Moens HJ, Zijlstra TR, et al. Treating to the target of remission in early rheumatoid arthritis is cost‐effective: results of the DREAM registry. BMC Musculoskelet Disord 2013;14:350.
    1. Gartner M, Mandl P, Radner H, Supp G, Machold KP, Aletaha D, et al. Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum 2013;65:2005–14.
    1. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009;60:1242–9.
    1. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823–7.
    1. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92.
    1. Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252–5.
    1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573–86.
    1. Son KM, Song SH, Lim SK, Seo YI, Kim HA. Characteristics of patients with rheumatoid arthritis in clinical remission: the many aspects of DAS28 remission. Clin Exp Rheumatol 2012;30:947–50.
    1. Sheehy C, Evans V, Hasthorpe H, Mukhtyar C. Revising DAS28 scores for remission in rheumatoid arthritis. Clin Rheumatol 2014;33:269–72.
    1. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011;13:R83.
    1. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64:1410–3.
    1. Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo‐Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316–21.
    1. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28‐Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score‐II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index‐5 (RADAI‐5), Chronic Arthritis Systemic Index (CASI), Patient‐Based Disease Activity Score With ESR (PDAS1) and Patient‐Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI‐RA). Arthritis Care Res (Hoboken) 2011;63 Suppl 11:S14–36.
    1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.
    1. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. Lancet 2008;372:375–82.
    1. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo‐Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open‐label, twelve‐week study. Arthritis Rheum 2008;59:32–41.
    1. Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev‐Petersen K, Luukkainen RK, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty‐four countries. Arthritis Rheum 2008;58:2642–51.
    1. Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daures JP, et al. Comparison of the long‐term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 2015;74:724–9.
    1. Heimans L, Boer KV, Koudijs KM, Visser K, Goekoop‐Ruiterman YP, Harbers JB, et al. Health‐related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. Arthritis Res Ther 2013;15:R173.
    1. Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDs. Rheumatology (Oxford) 2012;51:169–75.
    1. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient‐reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate‐to‐severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011;50:401–9.
    1. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al. Patient‐reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010;69:222–5.
    1. Van Tuyl LH, Felson DT, Wells G, Smolen J, Zhang B, Boers M. Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2010;62:108–17.
    1. Bykerk VP, Shadick N, Frits M, Bingham CO III, Jeffery I, Iannaccone C, et al. Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry. J Rheumatol 2014;41:227–34.
    1. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, et al. Using genetic and clinical data to understand response to disease‐modifying anti‐rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 2011;50:40–6.
    1. Iannaccone CK, Fossel A, Tsao H, Cui J, Weinblatt M, Shadick N. Factors associated with attrition in a longitudinal rheumatoid arthritis registry. Arthritis Care Res (Hoboken) 2013;65:1183–9.
    1. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford) 2007;46:975–9.
    1. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100–8.
    1. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625–36.
    1. Agency for Healthcare Research and Quality (AHRQ) . Calculating the US population‐based EQ‐5D index score: research initiative in clinical economics. Rockville (MD); August 2005. URL: .
    1. Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (M‐HAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ‐II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken) 2011;63 Suppl 11:S4–13.
    1. Pope JE, Khanna D, Norrie D, Ouimet JM. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 2009;36:254–9.
    1. Le QA, Doctor JN, Zoellner LA, Feeny NC. Minimal clinically important differences for the EQ‐5D and QWB‐SA in post‐traumatic stress disorder (PTSD): results from a doubly randomized preference trial (DRPT). Health Qual Life Outcomes 2013;11:59.
    1. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38–46.
    1. Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004;63:1576–80.
    1. Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al. Disease activity score–driven therapy versus routine care in patients with recent‐onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70:611–5.
    1. Conaghan PG, Hensor EM, Keenan AM, Morgan AW, Emery P. Persistently moderate DAS‐28 is not benign: loss of function occurs in early RA despite step‐up DMARD therapy. Rheumatology (Oxford) 2010;49:1894–9.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner